Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Purpose: Sorafenib and sunitinib are extensively used as first-line medications for metastatic renal cell carcinoma (mRCC). This meta-analysis was conducted to assess the antitumor efficacy, toxicity, and costs of the two drugs among mRCC patients. Materials and methods: PubMed, ScienceDirect, Scopu...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Huan, Liu, Wenfeng, He, Ting, Hong, Zhengdong, Yi, Fengming, Wei, Yiping, Zhang, Wenxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598399/
https://www.ncbi.nlm.nih.gov/pubmed/31293962
http://dx.doi.org/10.3389/fonc.2019.00479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598399/
https://www.ncbi.nlm.nih.gov/pubmed/31293962
http://dx.doi.org/10.3389/fonc.2019.00479

Ejemplares similares